| Literature DB >> 30863755 |
Moises Rodriguez-Gonzalez1, Maria Isabel Sanchez-Codez2, Manuel Lubian-Gutierrez2, Ana Castellano-Martinez3.
Abstract
BACKGROUND: Myocarditis is an important cause of morbidity and mortality in children, leading to long-term sequelae including chronic congestive heart failure, dilated cardiomyopathy, heart transplantation, and death. The initial diagnosis of myocarditis is usually based on clinical presentation, but this widely ranges from the severe sudden onset of a cardiogenic shock to asymptomatic patients. Early recognition is essential in order to monitor and start supportive treatment prior to the development of severe adverse events. Of note, many cases of fulminant myocarditis are usually misdiagnosed as otherwise minor conditions during the weeks before the unexpected deterioration. AIM: To provide diagnostic clues to make an early recognition of pediatric myocarditis. To investigate early predictors for poor outcomes.Entities:
Keywords: Cardiac magnetic resonance imaging; Children; Dilated cardiomyopathy; Echocardiography; Heart transplantation; Myocardial ischemia; Myocarditis; N-terminal pro-brain natriuretic peptide
Year: 2019 PMID: 30863755 PMCID: PMC6406197 DOI: 10.12998/wjcc.v7.i5.548
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.337
Figure 1Histogram showing the age distribution of myocarditis pediatric population. Most patients (70%) were children younger than 2-years-old (35%), and older than 12-years-old (35%).
Baseline characteristics at the time of hospital admission
| Age | Median (IQR) yr: 8 (1.5-12) |
| Male:Female gender | 2.23 |
| Evolution | Median (IQR) days from initial symptoms: 5 (2-10) |
| Visits to ED previously before diagnosis of myocarditis | Median (IQR) visits prior to admission: 2 (1-2); 1 visit (41), 2 visits (36), 3 visits (9), more than 3 visits (14) |
| Presenting symptoms (%) | Previous viral infection (69); Chest pain (40); Respiratory tract symptoms (cough, apnea, rhinorrhea) (38); Shortness of breath (35); Gastrointestinal tract symptoms (vomiting, abdominal pain, diarrhea) (33); Fever (31); Weakness, exercise or feeding intolerance (21); Palpitations (16); Lethargy (12); Syncope (4) |
| Physical exam (%) | Tachycardia (57); Tachypnea (52); Evidence of respiratory tract infection (44); Respiratory distress (35); Abnormal lung auscultation (31); Murmur (26); Systolic hypotension (24); Poor perfusion or diminished pulses (21); Gallop rhythm (20); Hepatomegaly (20); Edema (7); Cyanosis (2) |
| Cardiac syndrome (%) | ACS-like (34); Fulminant myocarditis (29); Congestive heart failure (23); Dysrhythmia (14) |
| Complementary exams | |
| Laboratory (%) | CRP > 60 mg/L (16); Troponin T > 10 ng/L (62); NT-proBNP > 600 pg/mL (40) |
| Chest X-Ray (%) | Cardiomegaly (35); Pulmonary edema (28); Pulmonary infiltrate (4%); Pleural effusion (2.5%) |
| ECG (%) | Abnormal ECG (93); Sinus tachycardia (61); Ischemic changes (57); Low voltage (50); SVT (2.5); VT (7); AVB (2.5); prolonged QT interval (2.5%) |
| Echocardiography (%) | Abnormal echocardiography (88): LV systolic dysfunction (50): severe (14), moderate (16), mild (20); Biventricular systolic dysfunction (10); Segmental wall motion abnormalities (38); LV dilation (43); Mitral regurgitation (69); Pericardial effusion (59) |
| Cardiac MRI (%) | MRI performed (50); Median days to realization from admission, 5 (3-9); Lake Louis criteria positive (86), equivocal (10), negative (4) |
| Microbiology (%) | Positive microbiology (47): Coxsakie (30); Parvovirus B19 (20); Adenovirus (15); EBV (15); CMV (10); Mycoplasma (10) |
| Treatment (%) | Any treatment (71): Diuretics (69); ACEI (69); Beta-blockers (64); Digoxin (14) Spironolactone (14); Antiarrhythmic (5); Inotropic support (35); Mechanical Ventilation (26); ECMO/VAD (2.5); Pacemaker (2.5) |
| Outcomes (%) | Hospitalization length of stay (d): Median 6 (IQR 3-13); Death (5), transplant (0) |
IQR: Interquartile range; GI: Gastrointestinal; SCD: Sudden cardiac death; ACS: Acute coronary syndrome; CRP: C-reactive protein; NT-proBNP: N-terminal pro-brain natriuretic peptide; ECG: Electrocardiogram; SVT: Supraventricular tachycardia; VT: Ventricular tachycardia; AVB: Atrioventricular block; LV: Left ventricle; MRI: Magnetic resonance imaging; EBV: Epstein-Barr virus; CMV: cytomegalovirus; ACEI: Angiotensin-converting-enzyme inhibitors; ECMO: Extracorporeal membrane oxygenation; VAD: Ventricular assist device.
Comparison between patients with acute coronary syndrome-like and fulminant myocarditis
| Age (yr), median (IQR) | 11 (5-12.5) | 1.6 (1-8) | < 0.001 | 10 (2-13) | 1.7 (0.9-3) | < 0.001 |
| Male sex, | 19 (71) | 19 (67) | 0.813 | 9 (75) | 20 (66) | 0.598 |
| Days from initial symptoms, median (IQR) | 2 (1-3) | 8.5 (4-12) | 0.005 | 9 (4.5-11) | 4 (2-10) | 0.017 |
| Visits prior to admission, median (IQR) | 1 (1-1) | 2 (2-3) | < 0.001 | 2.5 (2-3) | 1 (1-1) | < 0.001 |
| Viral prodromal, | 9 (31) | 5 (38) | 0.637 | 9 (31) | 3 (23) | 0.598 |
| Altered ECG, | 14 (100) | 25 (89) | 0.204 | 12 (100) | 27 (90) | 0.256 |
| CPR (mg/dl), median (IQR) | 5 (2.5-188) | 3 (2-144) | 0.179 | 29 (3-203) | 3 (2-144) | 0.095 |
| Troponin T (ng/mL), median (IQR) | 466 (89-800) | 51 (4-353) | 0.041 | 134 (71-431) | 70 (4-160) | 0.308 |
| NT-proBNP (pg/mL), median (IQR) | 137 (78-234) | 1960 (272-3175) | < 0.001 | 2900 (2207-6125) | 225 (105-561) | < 0.001 |
| LVEF (%), median (IQR) | 65 (62-67) | 41 (30-53) | < 0.001 | 32 (27-36) | 62 (45-66) | < 0.001 |
| LGE in cMRI ( | 10/14 (71) | 5/7 (71) | 1.000 | 0/1 (0) | 15/20 (75) | 0.105 |
| Positive Microbiology, | 9 (64) | 18 (64) | 1.000 | 8 (66) | 19 (63) | 0.839 |
| Poor outcomes, | 0 (0) | 7 (25) | 0.041 | 5 (41) | 2 (7) | 0.006 |
ACS-like: Acute coronary syndrome; FM: Fulminant myocarditis; IQR: Interquartile range; ECG: Electrocardiogram; CRP: C-reactive protein; NT-proBNP: N-terminal pro-brain natriuretic peptide; LVEF: Left ventricle ejection fraction; LGE: Late gadolinium enhancement; cMRI: Cardiac magnetic resonance imaging.
Comparison between patients with good and poor outcomes
| Age (years), median (IQR) | 11 (5-12.5) | 1.6 (1-8) | 0.026 | 10 (2-13) | 1.7 (0.9-3) | 0.014 |
| Male sex, | 14 (78) | 15 (62) | 0.289 | 24 (68) | 5 (71) | 0.881 |
| Evolution (days from initial symptoms), median (IQR) | 2.5 (2-10) | 7 (4-12) | 0.036 | 4 (2-10) | 7 (7-15) | 0.043 |
| Cardiac syndrome, | ||||||
| FM | 2 (8) | 10 (55) | < 0.001 | 7 (20) | 5 (71) | < 0.001 |
| CHF | 6 (25) | 4 (22) | 0.834 | 8 (23) | 2 (28) | 0.746 |
| Dysrhythmia | 3 (12) | 3 (16) | 0.793 | 6 (17) | 0 (0) | 0.237 |
| ACS-like | 13 (54) | 1 (5) | 0.001 | 14 (40) | 0 (0) | 0.041 |
| Viral prodromal, | 15 (62) | 14 (68) | 0.289 | 23 (65) | 6 (85) | 0.296 |
| Altered ECG, | 22 (91) | 17 (94) | 0.729 | 32 (91) | 7 (100) | 0.421 |
| CPR (mg/dL), median (IQR) | 4 (2-147) | 4 (3-125) | 0.443 | 4 (2-144) | 33 (3-156) | 0.415 |
| Troponin T (ng/mL), median (IQR) | 118 (5-580) | 91 (32-196) | 0.789 | 103 (5-610) | 52 (32-177) | 0.447 |
| NT-proBNP (pg/mL), median (IQR) | 291 (92-300) | 2700 (1955-4320) | < 0.001 | 300 (123-1955) | 5700 (2500-10321) | 0.002 |
| LVEF (%), median (IQR) | 65 (58-66) | 34 (28-41) | < 0.001 | 59 (41-66) | 29 (27-31) | < 0.001 |
| LVDD Z score > 2, | 9 (37) | 17 (94) | < 0.001 | 19 (54) | 7 (100) | 0.023 |
| Dyskinesia, | 11 (46) | 5 (27) | 0.233 | 15 (43) | 1 (14) | 0.155 |
| LGE in cMRI ( | 12 (75) | 3 (60) | 0.517 | 14 (70) | 1 (100) | 0.517 |
| Positive Microbiology, | 12 (50) | 8 (44) | 0.307 | 16 (45) | 4 (57) | 0.666 |
IQR: Interquartile range; CHF: Congestive heart failure; SCD: Sudden cardiac death; ACS: Acute coronary syndrome; FM: Fulminant myocarditis; CRP: C-reactive protein; LVEF: Left ventricle ejection fraction; LVDD: Left ventricle diastolic dysfunction; LGE: Late gadolinium enhancement; cMRI: Cardiac magnetic resonance imaging.
Predictors for poor outcome at hospital discharge
| Age < 2 yr | 8 (2-32) | 0.005 | ||
| Evolution > 7 d | 3 (0.9-11) | 0.038 | ||
| NT-proBNP > 5000 pg/mL | 15 (1.5-303) | 0.037 | ||
| LVEF < 30% | 60 (3-347) | 0.006 | 21 (2-456) | 0.027 |
Multivariate logistic regression was performed only on risk factors in univariate analyses for early and late poor outcome (age < 2 yr, evolution > 7 d, N-terminal pro-brain natriuretic peptide > 5000, left ventricular ejection fraction < 30%). Odds ratios refer to the change in odds of poor early and late outcome when the predictor variables are presents. LVEF: Left ventricular ejection fraction; NT-proBNP: N-terminal pro-brain natriuretic peptide; OR: Odds ratio; CI: Confidence interval.
Predictors for poor outcome at 1 yr from admission
| Age < 2 yr | 6 (1.1-37) | 0.046 | ||
| Evolution > 7 d | 10 (1.1-93) | 0.041 | ||
| NT-proBNP > 5000 pg/mL | 13 (1.4-122) | 0.024 | ||
| LVEF < 30% | 46 (4.4-392) | 0.001 | 8 (0.56-135) | 0.041 |
Multivariate logistic regression was performed only on risk factors in univariate analyses for early and late poor outcome (age < 2 yr, evolution > 7 d, N-terminal pro-brain natriuretic peptide > 5000, left ventricular ejection fraction < 30%). ORs refer to the change in odds of poor early and late outcome when the predictor variables are presents. LVEF: Left ventricular ejection fraction; NT-proBNP: N-terminal pro-brain natriuretic peptide; OR: Odds ratio; CI: Confidence interval.
Figure 2Correlations between left ventricular ejection fraction at admission and (A) N-terminal pro-brain natriuretic peptide levels, (B) age, and (C) days of evolution of the disease. NT-proBNP: N-terminal pro-brain natriuretic peptide.
Figure 3Area under receiver operating characteristic curve of N-terminal pro-brain natriuretic peptide for determining left ventricular ejection fraction < 30%. N-terminal pro-brain natriuretic peptide presented a high diagnostic accuracy for severe left ventricular systolic dysfunction on echocardiography with an area under curve of 0.931 (95%CI: 0.858-0.995, P < 0.001). The best cut-off point was 2000 pg/mL, with a sensitivity of 90%, specificity of 81%, positive predictive value of 60%, and negative predictive value of 96%.